About galecto inc - GLTO
Galecto, Inc. is a clinical-stage biotechnology company, which engages in developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and fibrotic diseases. The firm is also involved in the development of small molecule inhibitors of galectin-3 and LOXL2. The company was founded by Ulf Jörgen Nilsson, Hakon Leffler, Tariq Sethi, and Hans Thalsgård Schambye in 2011 and is headquartered in Boston, MA.
GLTO At a Glance
Galecto, Inc.
75 State Street
Boston, Massachusetts 02109
| Phone | 1-45-070-5210 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -21,439,000.00 | |
| Sector | Health Technology | Employees | 5 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
GLTO Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 0.423 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.44 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | -0.195 |
GLTO Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -4,287,800.00 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
GLTO Liquidity
| Current Ratio | 14.068 |
| Quick Ratio | 14.068 |
| Cash Ratio | 11.842 |
GLTO Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -77.454 |
| Return on Equity | -91.616 |
| Return on Total Capital | -134.803 |
| Return on Invested Capital | -88.795 |
GLTO Capital Structure
| Total Debt to Total Equity | 9.903 |
| Total Debt to Total Capital | 9.01 |
| Total Debt to Total Assets | 8.364 |
| Long-Term Debt to Equity | 9.82 |
| Long-Term Debt to Total Capital | 8.935 |